910-99-6

Basic information

• Product Name: 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate
• Synonyms: 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate;17-alpha-hydroxy-16-beta-methyl-3,20-dioxopregna- 1,4,9(11)-trien-21-yl acetate;17-Hydroxy-16-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate;Einecs 213-007-0
• CAS NO: 910-99-6
• Molecular Formula: C₂₄H₃₀O₅
• Molecular Weight: 398.492
• EINECS: 213-007-0
• Mol File: 910-99-6.mol
• Article Data: 13

Chemical Properties

• Melting Point: 205-207 °C
• Boiling Point: 560°C at 760 mmHg
• Flash Point: 189.6°C
• Appearance: /
• Density: 1.22g/cm³
• Vapor Pressure: 7.12E-15mmHg at 25°C
• Refractive Index: 1.58
• PKA: 12.48±0.70(Predicted)
• CAS DataBase Reference: 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate(910-99-6)
• EPA Substance Registry System: 17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate(910-99-6)

Safety Data

• Hazardous Substances Data: 910-99-6(Hazardous Substances Data)

Usage

General Description

17,21-dihydroxy-16beta-methylpregna-1,4,9(11)-triene-3,20-dione 21-acetate is a synthetic corticosteroid and derivative of cortisol that is used in the treatment of various inflammatory and autoimmune conditions. It acts as a potent anti-inflammatory and immunosuppressive agent by inhibiting the release of inflammatory cytokines and suppressing the activity of immune cells. The addition of the acetate group enhances its stability and prolongs its duration of action in the body. This chemical is commonly used in the form of creams, ointments, and inhalers for topical and localized treatment of skin conditions, asthma, and allergic reactions, as well as in oral or injectable formulations for systemic conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease. Despite its effectiveness, it can also cause several side effects such as skin thinning, increased risk of infections, and adrenal suppression, and should only be used under the supervision of a healthcare professional.

InChI:InChI=1/C24H30O5/c1-14-11-20-18-6-5-16-12-17(26)7-9-22(16,3)19(18)8-10-23(20,4)24(14,28)21(27)13-29-15(2)25/h7-9,12,14,18,20,28H,5-6,10-11,13H2,1-4H3/t14-,18+,20-,22-,23-,24-/m0/s1

Upstream product

• 37413-91-5 2-((10S,13S)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15-octahydro-3H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate 
• 2597-76-4 16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 
• 64-19-7 acetic acid 
• 18769-24-9 16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate 
• 144-55-8 sodium hydrogencarbonate 
• 124-63-0 methanesulfonyl chloride 
• 116846-77-6 21-Chloro-17α-hydroxy-16β-methylpregna-1,4,9(11)-triene-3,20-dione 
• 127-08-2 potassium acetate 
• 15375-21-0 androsta-1,4,9⁽¹¹⁾-triene-3,17-dione 
• 116816-73-0 17α-hydroxy-17β-cyano-androst-16β-methyl-1,4,9(11)-trien-3-one 
• 90039-90-0 androst-16β-methyl-1,4,9(11)-triene-3,17-dione 
• 135299-85-3 3,3-(1,2-Ethanediyldioxy)-17α-(1-ethoxyethoxy)-9α-hydroxy-16β-methylandrost-5-ene-17β-carbonitrile 
• 144602-43-7 Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(bis-benzenesulfinyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester 
• 144602-48-2 Acetic acid 2-[(8S,10S,13S,14S,16R,17S)-16-(benzenesulfinyl-phenylsulfanyl-methyl)-10,13-dimethyl-3-oxo-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl ester 

Downstream Products

• 13209-41-1 (10S,13S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,10,12,13,14,15,16,17-decahydro-3H-cyclopenta[a]phenanthren-3-one 
• 987-24-6 betamethasone 21-acetate 
• 912-38-9 21-acetoxy-9,11β-epoxy-17-hydroxy-16β-methyl-9β-pregna-1,4-diene-3,20-dione 

Relevant articles and documents

Preparation method of betamethasone epoxide

The invention provides a preparation method of a betamethasone epoxide, which comprises the steps of step 1, preparing a first reaction solution containing a compound II by using a compound I based onan esterification reaction; step 2, based on a bromine hydroxylation reaction, preparing a second reaction solution containing a compound III by using the first reaction solution; and 3, based on a hydrolysis reaction, preparing a betamethasone epoxide IV crude product by using the second reaction solution. The betamethasone epoxide IV is synthesized from the compound I by adopting a one-pot method, the method has the advantages of high yield, simplicity and safety in operation, low cost, small pollution and the like, and the method is stable and easy to realize industrial production.

Betamethasone intermediates or its preparation method of the analogue

The invention relates to a preparation method of a steroid hormone medicinal intermediate, in particular to a preparation method for a betamethasone intermediate or its analogue. The betamethasone intermediate or its analogue is prepared from a compound I by means of elimination reaction, methylation reaction, cyano-group substitution reaction, siloxy protective reaction, intramolecular nucleophilic substitution reaction and esterification reaction. The method provided by the invention has the characteristics of cheap raw materials, and high and stable yield. The reaction route is as the following, wherein R1 is Cl or Br, and R is H or hydrocarbonyl of C1-C10.

NON-HORMONAL STEROID MODULATORS OF NF-KB FOR TREATMENT OF DISEASE

The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.